{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:20:01Z","timestamp":1779175201531,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82100891"],"award-info":[{"award-number":["No.82100891"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82170847"],"award-info":[{"award-number":["No.82170847"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82170824"],"award-info":[{"award-number":["No.82170824"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Thyroid dysfunction is the most common immune-related adverse event during anti-programmed cell death 1 (anti-PD-1) therapy. In this study, we monitored patients with advanced malignant tumors who received anti-PD-1 therapy to observe the characteristic of anti-PD-1 therapy-induced thyroid dysfunction and its correlation with prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with advanced carcinoma treated with anti-PD-1 therapy were evaluated for thyroid function at baseline and after treatment initiation from August 2020 to March 2022. Seventy-three patients were finally included in the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among these patients, 19 (26.03%) developed thyroid dysfunction after receiving anti-PD-1 therapy. Primary hypothyroidism and thyrotoxicosis were the most common clinical manifestation. Anti-PD-1-induced thyroid dysfunction occurred 63 (26\u2013131) days after administration; thyrotoxicosis appeared earlier than primary hypothyroidism. In Kaplan\u2013Meier survival analysis, the progression-free survival (PFS) of the thyroid dysfunction group was better than that of the no thyroid dysfunction group (227 (95% confidence interval (CI) 50.85\u2013403.15) days vs 164 (95% CI 77.76\u2013250.24) days, <jats:italic>p<\/jats:italic>\u2009=\u20090.026). Male patients had better PFS than female patients (213 (95% CI 157.74\u2013268.26) days vs 74 (95% CI 41.23\u2013106.77) days, <jats:italic>p<\/jats:italic>\u2009=\u20090.031). In cox proportional hazards regression model, anti-PD-1-induced thyroid dysfunction remained an independent predictor of better PFS (hazard ratio (HR)\u2009=\u20090.339(0.136\u20130.848), <jats:italic>p<\/jats:italic>\u2009=\u20090.021).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Thyroid dysfunction is a common immune-related adverse events in advanced cancer patients treated with anti-PD-1 therapy and predicts a better prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This study was retrospectively registered with Trial ClinicalTrials.gov (NCT05593744) on October 25, 2022.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-05364-z","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T17:02:03Z","timestamp":1694797323000},"page":"16501-16510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma"],"prefix":"10.1007","volume":"149","clinical-trial-number":[{"clinical-trial-number":"nct05593744","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yiran","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lusi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"5364_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.05.013","author":"D \u00c1lvarez-Sierra","year":"2019","unstructured":"\u00c1lvarez-Sierra D, Mar\u00edn-S\u00e1nchez A, Ruiz-Bl\u00e1zquez P, de Jes\u00fas Gil C, Iglesias-Felip C, Gonz\u00e1lez \u00d3, Casteras A, Costa RF, Nuciforo P, Colobran R, Pujol-Borrell R (2019) Analysis of the PD-1\/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun. https:\/\/doi.org\/10.1016\/j.jaut.2019.05.013","journal-title":"J Autoimmun."},{"issue":"18","key":"5364_CR2","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA (2016) Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 375(18):1767\u20131778. https:\/\/doi.org\/10.1056\/NEJMra1514296","journal-title":"N Engl J Med"},{"issue":"8","key":"5364_CR3","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s40618-020-01480-6","volume":"44","author":"L Brilli","year":"2021","unstructured":"Brilli L, Danielli R, Campanile M, Secchi C, Ciuoli C, Calabr\u00f2 L, Pilli T, Cartocci A, Pacini F, Di Giacomo AM, Castagna MG (2021) Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. J Endocrinol Invest 44(8):1719\u20131726. https:\/\/doi.org\/10.1007\/s40618-020-01480-6","journal-title":"J Endocrinol Invest"},{"issue":"S11","key":"5364_CR4","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/cncr.30444","volume":"123","author":"EH Byrne","year":"2017","unstructured":"Byrne EH, Fisher DE (2017) Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer 123(S11):2143\u20132153. https:\/\/doi.org\/10.1002\/cncr.30444","journal-title":"Cancer"},{"issue":"2","key":"5364_CR5","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/ERC-18-0320","volume":"26","author":"F Castinetti","year":"2019","unstructured":"Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F (2019) French endocrine society guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer 26(2):G1\u2013G18. https:\/\/doi.org\/10.1530\/ERC-18-0320","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"5364_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40618-017-0778-8","volume":"41","author":"P Chalan","year":"2018","unstructured":"Chalan P, Di Dalmazi G, Pani F, De Remigis A, Corsello A, Caturegli P (2018) Thyroid dysfunctions secondary to cancer immunotherapy. J Endocrinol Invest 41(6):625\u2013638. https:\/\/doi.org\/10.1007\/s40618-017-0778-8","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"5364_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40(1):17\u201365. https:\/\/doi.org\/10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"issue":"6","key":"5364_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","volume":"19","author":"F Conforti","year":"2018","unstructured":"Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A (2018) Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis. Lancet Oncol 19(6):737\u2013746. https:\/\/doi.org\/10.1016\/S1470-2045(18)30261-4","journal-title":"Lancet Oncol"},{"issue":"11","key":"5364_CR9","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1210\/jc.2016-2300","volume":"101","author":"J de Filette","year":"2016","unstructured":"de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B (2016) Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 101(11):4431\u20134439. https:\/\/doi.org\/10.1210\/jc.2016-2300","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"5364_CR10","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryder M (2017) Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 102(8):2770\u20132780. https:\/\/doi.org\/10.1210\/jc.2017-00448","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"5364_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.autrev.2010.04.003","volume":"9","author":"RK Dinesh","year":"2010","unstructured":"Dinesh RK, Hahn BH, Singh RP (2010) PD-1, gender, and autoimmunity. Autoimmun Rev 9(8):583\u2013587. https:\/\/doi.org\/10.1016\/j.autrev.2010.04.003","journal-title":"Autoimmun Rev"},{"issue":"1","key":"5364_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1172\/JCI131194","volume":"130","author":"M Dougan","year":"2020","unstructured":"Dougan M, Pietropaolo M (2020) Time to dissect the autoimmune etiology of cancer antibody immunotherapy. J Clin Invest 130(1):51\u201361. https:\/\/doi.org\/10.1172\/JCI131194","journal-title":"J Clin Invest"},{"key":"5364_CR13","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.12.17","author":"S Espa\u00f1a","year":"2020","unstructured":"Espa\u00f1a S, Montes P\u00e9rez, de Oca A, Marques-Pamies M, Cucurull M, Domenech M, Velarde JM, Salinas I, Moran T, Etxaniz O (2020) Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution. Transl Lung Cancer Res. https:\/\/doi.org\/10.21037\/tlcr.2019.12.17","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"5364_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","volume":"19","author":"SM Ferrari","year":"2018","unstructured":"Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, Antonelli A (2018) Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord 19(4):325\u2013333. https:\/\/doi.org\/10.1007\/s11154-018-9463-2","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"5364_CR15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886\u2013894. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1136","journal-title":"Clin Cancer Res"},{"key":"5364_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00794","author":"MR Gubbels Bupp","year":"2018","unstructured":"Gubbels Bupp MR, Jorgensen TN (2018) Androgen-induced immunosuppression. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.00794","journal-title":"Front Immunol."},{"key":"5364_CR17","doi-asserted-by":"publisher","unstructured":"Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264-iv266]. Ann Oncol. 2017;28(suppl_4):iv119-iv142. doi:https:\/\/doi.org\/10.1093\/annonc\/mdx225","DOI":"10.1093\/annonc\/mdx225"},{"key":"5364_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29\u201339. https:\/\/doi.org\/10.1016\/j.intimp.2018.06.001","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"5364_CR19","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jamaoncol.2019.1747","volume":"5","author":"D Kazandjian","year":"2019","unstructured":"Kazandjian D, Gong Y, Keegan P, Pazdur R, Blumenthal GM (2019) Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer. JAMA Oncol 5(10):1481\u20131485. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1747","journal-title":"JAMA Oncol"},{"key":"5364_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","volume":"64","author":"S Khan","year":"2020","unstructured":"Khan S, Gerber DE (2020) Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol 64:93\u2013101. https:\/\/doi.org\/10.1016\/j.semcancer.2019.06.012","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"5364_CR21","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1111\/cas.13800","volume":"109","author":"S Kimbara","year":"2018","unstructured":"Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, Yamazaki N, Kitano S, Yamamoto N, Ohe Y (2018) Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci 109(11):3583\u20133590. https:\/\/doi.org\/10.1111\/cas.13800","journal-title":"Cancer Sci"},{"issue":"10","key":"5364_CR22","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1089\/thy.2020.0075","volume":"30","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Gustafson MP, Bornschlegl S, Kottschade L, Delivanis DA, Dietz AB, Gandhi M, Ryder M (2020) Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal t lymphocyte subpopulations. Thyroid 30(10):1440\u20131450. https:\/\/doi.org\/10.1089\/thy.2020.0075","journal-title":"Thyroid"},{"issue":"2","key":"5364_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-020-02664-y","volume":"70","author":"J Lima Ferreira","year":"2021","unstructured":"Lima Ferreira J, Costa C, Marques B, Castro S, Victor M, Oliveira J, Santos AP, Sampaio IL, Duarte H, Marques AP, Torres I (2021) Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors. Cancer Immunol Immunother 70(2):299\u2013309. https:\/\/doi.org\/10.1007\/s00262-020-02664-y","journal-title":"Cancer Immunol Immunother"},{"key":"5364_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.691002","author":"H Liu","year":"2021","unstructured":"Liu H, Yang XL, Yang XY, Dong ZR, Chen ZQ, Hong JG, Li T (2021) The prediction potential of the pretreatment lung immune prognostic index for the therapeutic outcomes of immune checkpoint inhibitors in patients with solid cancer: a systematic review and meta-analysis. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.691002","journal-title":"Front Oncol."},{"issue":"18","key":"5364_CR25","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-21-0921","volume":"27","author":"J Luo","year":"2021","unstructured":"Luo J, Martucci VL, Quandt Z, Groha S, Murray MH, Lovly CM, Rizvi H, Egger JV, Plodkowski AJ, Abu-Akeel M, Schulze I, Merghoub T, Cardenas E, Huntsman S, Li M, Hu D, Gubens MA, Gusev A, Aldrich MC, Hellmann MD, Ziv E (2021) Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with pd-1 blockade in non-small cell lung cancer. Clin Cancer Res 27(18):5131\u20135140. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0921","journal-title":"Clin Cancer Res"},{"key":"5364_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111713","author":"DE Meyers","year":"2019","unstructured":"Meyers DE, Stukalin I, Vallerand IA, Lewinson RT, Suo A, Dean M, North S, Pabani A, Cheng T, Heng DYC, Bebb DG, Morris DG (2019) The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11111713","journal-title":"Cancers (Basel)"},{"issue":"3","key":"5364_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zer\u00f3n-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4(3):351\u2013357. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4771","journal-title":"JAMA Oncol"},{"key":"5364_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02279","author":"VR Moulton","year":"2018","unstructured":"Moulton VR (2018) Sex hormones in acquired immunity and autoimmune disease. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.02279","journal-title":"Front Immunol."},{"issue":"9","key":"5364_CR29","doi-asserted-by":"publisher","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","volume":"106","author":"CA Muir","year":"2021","unstructured":"Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM (2021) Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab 106(9):e3704\u2013e3713. https:\/\/doi.org\/10.1210\/clinem\/dgab263","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"5364_CR30","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41416-020-0736-7","volume":"122","author":"N Okada","year":"2020","unstructured":"Okada N, Iwama S, Okuji T, Kobayashi T, Yasuda Y, Wada E, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Hase T, Morise M, Kanda M, Yokota K, Hashimoto N, Ando M, Fujimoto Y, Nagino M, Kodera Y, Fujishiro M, Hibi H, Sone M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H (2020) Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. Br J Cancer 122(6):771\u2013777. https:\/\/doi.org\/10.1038\/s41416-020-0736-7","journal-title":"Br J Cancer"},{"issue":"3","key":"5364_CR31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583\u2013589. https:\/\/doi.org\/10.1093\/annonc\/mdw640","journal-title":"Ann Oncol"},{"issue":"4","key":"5364_CR32","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/cancers13040860","volume":"13","author":"A Paderi","year":"2021","unstructured":"Paderi A, Giorgione R, Giommoni E, Mela MM, Rossi V, Doni L, Minervini A, Carini M, Pillozzi S, Antonuzzo L (2021) Association between immune related adverse events and outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Cancers (Basel). 13(4):860. https:\/\/doi.org\/10.3390\/cancers13040860","journal-title":"Cancers (Basel)."},{"key":"5364_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","volume":"65","author":"DB Page","year":"2014","unstructured":"Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD (2014) Immune modulation in cancer with antibodies. Annu Rev Med 65:185\u2013202. https:\/\/doi.org\/10.1146\/annurev-med-092012-112807","journal-title":"Annu Rev Med"},{"key":"5364_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1427779","author":"Y Pan","year":"2022","unstructured":"Pan Y, Si H, Jia R, Deng G, Yan H, Fan M, Gou M, Chen S, Zhang N, Shi Y, Qian N, Dai G (2022) Analysis of a systemic inflammatory biomarker in advanced bile tract carcinoma treated with Anti-PD-1 therapy: Prognostic and predictive significance of lung immune prognostic index score. J Oncol. https:\/\/doi.org\/10.1155\/2022\/1427779","journal-title":"J Oncol"},{"issue":"6","key":"5364_CR35","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH (2019) Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol 40(6):511\u2013523. https:\/\/doi.org\/10.1016\/j.it.2019.04.002","journal-title":"Trends Immunol"},{"issue":"2","key":"5364_CR36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"issue":"3","key":"5364_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40618-019-01112-8","volume":"43","author":"EM Presotto","year":"2020","unstructured":"Presotto EM, Rastrelli G, Desideri I, Scotti V, Gunnella S, Pimpinelli N, Vaccher E, Bearz A, Di Costanzo F, Bruggia M, Mini E, Maggi M, Peri A (2020) Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. J Endocrinol Invest 43(3):337\u2013345. https:\/\/doi.org\/10.1007\/s40618-019-01112-8","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"5364_CR38","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12020-021-02750-w","volume":"74","author":"R Rubino","year":"2021","unstructured":"Rubino R, Marini A, Roviello G, Presotto EM, Desideri I, Ciardetti I, Brugia M, Pimpinelli N, Antonuzzo L, Mini E, Livi L, Maggi M, Peri A (2021) Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. Endocrine 74(1):172\u2013179. https:\/\/doi.org\/10.1007\/s12020-021-02750-w","journal-title":"Endocrine"},{"issue":"7","key":"5364_CR39","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00262-020-02802-6","volume":"70","author":"P Thuillier","year":"2021","unstructured":"Thuillier P, Joly C, Alavi Z, Crouzeix G, Descourt R, Quere G, Kerlan V, Roudaut N (2021) Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study. Cancer Immunol Immunother 70(7):2023\u20132033. https:\/\/doi.org\/10.1007\/s00262-020-02802-6","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"5364_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16(5):275\u2013287. https:\/\/doi.org\/10.1038\/nrc.2016.36","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"5364_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB (2021) Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 17(7):389\u2013399. https:\/\/doi.org\/10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"5364_CR42","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ijc.33813","volume":"150","author":"L Xu","year":"2022","unstructured":"Xu L, Leng C, Chen L, Dong H, Chen Y, Chen X (2022) Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma. Int J Cancer 150(3):472\u2013481. https:\/\/doi.org\/10.1002\/ijc.33813","journal-title":"Int J Cancer"},{"key":"5364_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb7495","author":"Y Yasuda","year":"2021","unstructured":"Yasuda Y, Iwama S, Sugiyama D, Okuji T, Kobayashi T, Ito M, Okada N, Enomoto A, Ito S, Yan Y, Sugiyama M, Onoue T, Tsunekawa T, Ito Y, Takagi H, Hagiwara D, Goto M, Suga H, Banno R, Takahashi M, Nishikawa H, Arima H (2021) CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abb7495","journal-title":"Sci Transl Med"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05364-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05364-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05364-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:09:23Z","timestamp":1699956563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05364-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":43,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["5364"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05364-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"4 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Qilu Hospital of Shandong University and retrospectively registered with ClinicalTrials.gov (NCT 05593744).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants signed informed written consent before being enrolled in the study. This study was performed in line with the principles of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. Because this is not a case study. We collect data anonymously. We present the results by analyzing a large number of quantitative data, and there will be no information leakage of any participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}